Market Overview

A Peek Into The Market Before The Trading Starts

A Peek Into The Market Before The Trading Starts
Related PAY
VeriFone Systems: Imperial Stays On Sidelines
Mid-Afternoon Market Update: Dow Rises Over 100 Points; Proteon Therapeutics Shares Slide
Tracking Alex Roepers' Atlantic Investment Management Portfolio - Q4 2016 Update (Seeking Alpha)
Related PWR
Earnings Scheduled For February 21, 2017
Benzinga's Top Downgrades
Will Heavy Construction's Rebound Receive A Trump Infrastructure Boost? (Investor's Business Daily)

Pre-open movers US stock futures are lower this morning, as investors are awaiting economic data. Futures for the Dow Jones Industrial Average tumbled 31 points to 13,858.00 and S&P 500 index futures fell 3 points to 1,504.10. Nasdaq 100 futures dropped 11 points to 2,726.50.

A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index fell 1.20%, London's FTSE 100 Index dipped 1.56%, French CAC 40 Index fell 1.72% and German DAX 30 index declined 1.73%.

Asian markets ended lower, with Japan's Nikkei Stock Average dropping 1.39%, China's Shanghai Composite falling 2.97% and Australia's S&P/ASX 200 dropping 2.26%. Hong Kong's Hang Seng Index tumbled 1.72% and India's Sensex fell 1.62%.

Broker Recommendation Analysts at Piper Jaffray downgraded VeriFone Systems (NYSE: PAY) from “overweight” to “neutral.” The target price for VeriFone has been lowered from $42 to $24.

VeriFone shares tumbled 35.25% to $20.65 in pre-market trading.

Breaking news

  • Quanta Services (NYSE: PWR) reported a 49% rise in its fourth-quarter earnings. To read the full news, click here.
  • Sirona Dental Systems (NASDAQ: SIRO) announced that Jeffrey T. Slovin has become its Chief Executive Officer in accordance with the succession plan previously announced on November 16, 2012. To read the full news, click here.
  • Host Hotels & Resorts (NYSE: HST) reported a 12% drop in its fourth-quarter profit. To read the full news, click here.
  • Repros Therapeutics (NASDAQ: RPRX) today provided a clinical update of its Androxal^® Phase 3 program following receipt of written guidance from the FDA. To read the full news, click here.

Posted-In: Piper Jaffray US Stock FuturesNews Futures Global Pre-Market Outlook Markets


Related Articles (HST + PAY)

View Comments and Join the Discussion!